Elite Journal of Medicine. Volume 1 issue 1(2023), Pp. 31-44
https://epjournals.com/journals/EJM

Ceruloplasmin and HIV-Associated Hematological Abnormalities: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hematological abnormalities are common complications of HIV infection, encompassing a spectrum of disorders including cytopenias, coagulopathies, and dysregulated iron metabolism. Ceruloplasmin, a multifunctional glycoprotein with diverse physiological roles, has emerged as a potential modulator of hematological parameters in the context of HIV infection. This comprehensive review explores the intricate relationship between ceruloplasmin and HIV-associated hematological abnormalities, examining its involvement in erythropoiesis, thrombopoiesis, coagulation, and iron metabolism. We discuss the mechanisms underlying ceruloplasmin's effects on hematological parameters, its implications for disease pathogenesis, and potential therapeutic interventions targeting ceruloplasmin-mediated pathways.

Keywords: *Ceruloplasmin, HIV, hematological abnormalities, erythropoiesis, thrombopoiesis, coagulation, iron metabolism, therapeutic interventions.*

Introduction

Hematological abnormalities represent a significant clinical manifestation of HIV infection, encompassing a broad spectrum of disorders that include anemia, thrombocytopenia, coagulopathies, and dysregulated iron metabolism. These abnormalities can arise from various factors, including direct viral effects, immune dysregulation, opportunistic infections, medication side effects, and underlying comorbidities. Understanding the underlying mechanisms driving hematological abnormalities in HIV-infected individuals is crucial for effective management and improved patient outcomes. Ceruloplasmin, a multifunctional glycoprotein primarily synthesized in the liver, has emerged as a potential mediator of hematological parameters in the context of HIV infection. Traditionally recognized for its role in copper metabolism and antioxidant defense, ceruloplasmin's diverse physiological functions suggest its involvement in erythropoiesis,

thrombopoiesis, coagulation, and iron metabolism, all of which are perturbed in HIV-infected individuals. Investigating the role of ceruloplasmin in HIV-associated hematological abnormalities may provide valuable insights into disease pathogenesis and identify novel therapeutic targets for intervention.[1-10] This review aims to explore the intricate relationship between ceruloplasmin and HIV-associated hematological abnormalities, synthesizing existing literature and highlighting key findings from experimental and clinical studies.

Ceruloplasmin and Erythropoiesis

Ceruloplasmin, traditionally recognized for its role in copper metabolism and antioxidant defense, has garnered attention for its potential involvement in erythropoiesis, the process of red blood cell production. Erythropoiesis is a tightly regulated process orchestrated by various factors, including erythropoietin (EPO), iron availability, and cytokine signaling. Ceruloplasmin's multifaceted functions, including its role in iron metabolism and oxidative stress regulation, suggest its potential influence on erythropoiesis in both physiological and pathological conditions, including HIV infection. Iron availability is a critical determinant of erythropoiesis, as iron serves as an essential cofactor for heme synthesis, a key component of hemoglobin. Ceruloplasmin plays a central role in iron metabolism by facilitating the conversion of ferrous iron (Fe^2+) to ferric iron (Fe^3+), allowing for its transport and storage. Dysregulation of ceruloplasmin-mediated iron metabolism may lead to iron deficiency or iron overload, both of which can impact erythropoiesis. In HIV-infected individuals, alterations in iron metabolism, such as iron sequestration by immune cells or chronic inflammation-induced hypoferremia, may contribute to erythropoietic dysfunction and anemia.[11-20]

Furthermore, ceruloplasmin's antioxidant properties may indirectly influence erythropoiesis by protecting erythrocytes from oxidative damage and premature destruction. Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, can impair erythrocyte function and survival. Ceruloplasmin's ability to scavenge free radicals and inhibit lipid peroxidation may help preserve erythrocyte integrity and prolong their lifespan, thereby supporting erythropoiesis. In addition to its role in iron metabolism and oxidative stress regulation, ceruloplasmin may modulate erythropoietin (EPO) signaling and erythroid progenitor cell differentiation. EPO, a glycoprotein hormone produced primarily by the kidney in response to hypoxia, stimulates erythropoiesis by promoting the proliferation and differentiation of erythroid progenitor cells. Ceruloplasmin's interactions with EPO receptors or its downstream signaling pathways may influence EPO responsiveness and erythroid progenitor cell fate, thereby impacting erythropoiesis in HIV-infected individuals.[21-30]

Ceruloplasmin and Thrombopoiesis

Ceruloplasmin, a key player in copper metabolism and antioxidant defense, is increasingly recognized for its potential involvement in thrombopoiesis, the process of platelet production. Thrombopoiesis is a complex and tightly regulated process that occurs primarily in the bone marrow, orchestrated by various growth factors, cytokines, and signaling pathways. While the exact role of ceruloplasmin in thrombopoiesis remains to be fully elucidated, emerging evidence

suggests its contribution to platelet production and homeostasis, with implications for hematological disorders such as thrombocytopenia observed in conditions like HIV infection. One potential mechanism by which ceruloplasmin may influence thrombopoiesis is through its role in copper metabolism. Ceruloplasmin, as a copper-binding protein, plays a crucial role in copper transport and utilization within the body. Copper is an essential cofactor for various enzymes involved in cellular processes, including hematopoiesis. Dysregulation of ceruloplasmin-mediated copper metabolism may impact megakaryopoiesis, the process by which megakaryocytes, the precursor cells of platelets, proliferate and mature, thereby affecting platelet production.[31-40]

Moreover, ceruloplasmin's antioxidant properties may indirectly influence thrombopoiesis by protecting megakaryocytes and platelets from oxidative stress-induced damage. Megakaryocytes, as highly specialized cells responsible for platelet production, are particularly vulnerable to oxidative stress due to their high metabolic activity and exposure to reactive oxygen species (ROS). Ceruloplasmin's ability to scavenge free radicals and inhibit lipid peroxidation may help preserve megakaryocyte function and platelet integrity, thereby supporting thrombopoiesis. In addition to its role in copper metabolism and oxidative stress regulation, ceruloplasmin may modulate signaling pathways involved in megakaryocyte differentiation and platelet production. Growth factors such as thrombopoietin (TPO) play a crucial role in regulating megakaryopoiesis by stimulating the proliferation and differentiation of megakaryocyte progenitor cells. Ceruloplasmin's interactions with TPO receptors or its downstream signaling cascades may influence TPO responsiveness and megakaryocyte maturation, thereby impacting thrombopoiesis. Furthermore, dysregulation of ceruloplasmin-mediated pathways may contribute to thrombocytopenia, a common hematological complication observed in HIV infection. HIV-associated thrombocytopenia may result from various factors, including direct viral effects on megakaryocytes, immune dysregulation, and medication side effects. Ceruloplasmin's involvement in thrombopoiesis and platelet homeostasis suggests its potential as a therapeutic target for managing thrombocytopenia in HIV-infected individuals, although further research is needed to elucidate the specific mechanisms underlying its effects.[41-70]

Ceruloplasmin and Coagulation

Ceruloplasmin, a multifunctional glycoprotein primarily recognized for its role in copper metabolism and antioxidant defense, has garnered attention for its potential involvement in coagulation pathways. Coagulation is a tightly regulated process that maintains hemostasis by forming blood clots to prevent excessive bleeding. While the precise mechanisms underlying ceruloplasmin's effects on coagulation remain to be fully elucidated, emerging evidence suggests its contribution to coagulation balance, with implications for hematological disorders such as hypercoagulability and bleeding tendencies observed in conditions like HIV infection. One potential mechanism by which ceruloplasmin may influence coagulation is through its interactions with coagulation factors and endothelial cells. Ceruloplasmin has been shown to bind to and modulate the activity of certain coagulation factors, such as factor V and factor VIII, which play key roles in the coagulation cascade. Dysregulation of ceruloplasmin-mediated coagulation factor interactions may disrupt coagulation balance and predispose individuals to thrombotic or bleeding complications.[71-75]

Moreover, ceruloplasmin's antioxidant properties may indirectly impact coagulation by protecting endothelial cells from oxidative stress-induced damage. Endothelial dysfunction, characterized by impaired endothelial cell function and integrity, is associated with dysregulated coagulation and increased thrombotic risk. Ceruloplasmin's ability to scavenge free radicals and inhibit lipid peroxidation may help preserve endothelial cell function and vascular integrity, thereby maintaining coagulation homeostasis. In addition to its role in modulating coagulation factor activity and endothelial function, ceruloplasmin may influence fibrinolysis, the process by which blood clots are dissolved. Plasmin, the key enzyme involved in fibrinolysis, is activated from its precursor plasminogen by plasminogen activators such as tissue plasminogen activator (tPA). Ceruloplasmin has been shown to interact with plasminogen and modulate its activity, suggesting a potential role in regulating fibrinolysis and clot dissolution. Furthermore, dysregulation of ceruloplasmin-mediated pathways may contribute to coagulation abnormalities observed in HIV infection, including hypercoagulability and bleeding tendencies. HIV-associated coagulation abnormalities may result from various factors, including chronic inflammation, immune dysregulation, medication side effects, and opportunistic infections. Ceruloplasmin's involvement in coagulation pathways suggests its potential as a therapeutic target for managing coagulation disorders in HIV-infected individuals, although further research is needed to elucidate the specific mechanisms underlying its effects.[76-95]

Ceruloplasmin and Iron Metabolism

Ceruloplasmin, a vital glycoprotein primarily produced in the liver, plays a pivotal role in iron metabolism, making it a significant player in hematological health. Iron, an essential micronutrient, is involved in various cellular processes, including oxygen transport, energy production, and DNA synthesis. Ceruloplasmin acts as a ferroxidase enzyme, facilitating the conversion of ferrous iron (Fe^2+) to ferric iron (Fe^3+), a crucial step for iron transport and storage in the body. The ferroxidase activity of ceruloplasmin enables it to regulate systemic iron homeostasis by promoting iron oxidation and facilitating its binding to transferrin, the primary iron transport protein in the bloodstream. This process ensures the safe transport of iron to various tissues and organs, including the bone marrow for erythropoiesis, the liver for storage, and other tissues for metabolic functions. Dysregulation of ceruloplasmin-mediated iron metabolism can lead to iron overload or deficiency, both of which have profound implications for hematological health. In conditions of iron overload, such as hereditary hemochromatosis or transfusion-dependent disorders, ceruloplasmin's ferroxidase activity becomes particularly crucial in preventing iron-mediated oxidative damage. By promoting iron sequestration and limiting the formation of reactive oxygen species (ROS), ceruloplasmin helps mitigate the adverse effects of iron overload on cellular function and tissue integrity. Conversely, ceruloplasmin deficiency or dysfunction can exacerbate iron overload and predispose individuals to oxidative stress-related complications, including tissue damage and organ dysfunction. On the other hand, ceruloplasmin also plays a critical role in preventing iron deficiency and anemia by facilitating iron release from storage sites and promoting its incorporation into erythrocytes for hemoglobin synthesis. In conditions of iron deficiency, ceruloplasmin's ferroxidase activity helps mobilize iron stores from hepatocytes and macrophages, ensuring an adequate supply of iron for erythropoiesis. Additionally, ceruloplasmin's antioxidant properties protect erythrocytes from oxidative damage,

thereby preserving their function and lifespan. In the context of HIV infection, dysregulation of ceruloplasmin-mediated iron metabolism may contribute to hematological abnormalities observed in affected individuals. HIV-associated anemia, often characterized by impaired erythropoiesis and reduced hemoglobin levels, may result from alterations in iron metabolism, including iron sequestration by immune cells or chronic inflammation-induced hypoferremia. Similarly, dysregulated iron metabolism may contribute to other hematological complications, such as thrombocytopenia and coagulation disorders, in HIV-infected individuals.[96-100]

Therapeutic Interventions Targeting Ceruloplasmin

Therapeutic interventions targeting ceruloplasmin hold promise for managing a variety of hematological disorders, including those associated with HIV infection. These interventions aim to modulate ceruloplasmin activity or expression, restore redox balance, and mitigate the adverse effects of dysregulated iron metabolism. Several potential therapeutic strategies have been proposed, ranging from antioxidant interventions to ceruloplasmin modulation and iron chelation therapies. One potential therapeutic approach involves the use of antioxidants to mitigate oxidative stress and preserve ceruloplasmin function. Antioxidants such as vitamin C, vitamin E, and N-acetylcysteine (NAC) have been shown to enhance ceruloplasmin activity and protect against oxidative damage in various disease states. By augmenting ceruloplasmin-mediated antioxidant defenses, antioxidant interventions may help alleviate oxidative stress burden and mitigate the progression of hematological disorders associated with HIV infection. Another therapeutic strategy involves directly modulating ceruloplasmin expression or activity to restore redox balance and iron homeostasis. Small molecule inhibitors or activators targeting ceruloplasmin synthesis, secretion, or enzymatic activity may offer potential therapeutic benefits in conditions characterized by ceruloplasmin dysregulation. By fine-tuning ceruloplasmin levels and function, these interventions may help restore iron metabolism and mitigate the adverse effects of iron overload or deficiency on hematological health.[101-104]

Furthermore, iron chelation therapies represent another potential therapeutic approach for managing hematological disorders associated with dysregulated ceruloplasmin-mediated iron metabolism. Iron chelators such as deferoxamine, deferiprone, and deferasirox bind to excess iron in the bloodstream and tissues, facilitating its excretion and reducing iron-mediated oxidative damage. Iron chelation therapies may be particularly beneficial in conditions characterized by iron overload, such as hereditary hemochromatosis or transfusion-dependent disorders, where ceruloplasmin-mediated iron metabolism is dysregulated. Combinatorial approaches combining antioxidant interventions, ceruloplasmin modulation, and iron chelation therapies may offer synergistic effects and enhanced therapeutic efficacy in managing hematological disorders associated with HIV infection. By simultaneously targeting multiple pathways involved in oxidative stress, iron metabolism, and hematopoiesis, these combination therapies may help restore hematological parameters and improve clinical outcomes in affected individuals.[105-112]

Conclusion

Therapeutic interventions targeting ceruloplasmin represent promising strategies for managing a variety of hematological disorders associated with HIV infection. Ceruloplasmin, a multifunctional glycoprotein involved in copper metabolism, antioxidant defense, and iron homeostasis, plays a critical role in maintaining hematological health. Dysregulation of ceruloplasmin-mediated pathways can lead to oxidative stress, iron overload or deficiency, and impaired hematopoiesis, contributing to the development and progression of hematological complications observed in HIV-infected individuals. Antioxidant interventions, ceruloplasmin modulation, and iron chelation therapies offer potential therapeutic approaches for restoring redox balance, mitigating iron-mediated oxidative damage, and improving hematological parameters in affected individuals. Combinatorial approaches combining these therapeutic strategies may offer synergistic effects and enhanced therapeutic efficacy, addressing multiple pathways involved in hematological disorders associated with HIV infection.

References

1. World Health Organization. Global health sector response to HIV, 2000-2015: focus on innovations in Africa: progress report. World Health Organization; 2015.
2. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Annals of internal medicine. 2011;154(11):766-771.
3. Waldman AJ, Balskus EP. The human microbiota, infectious disease, and global health: challenges and opportunities. ACS infectious diseases. 2018;4(1):14-26.
4. Chan M. Ten years in public health 2007-2017: report by dr margaret chan director-general world health organization. World Health Organization; 2018.
5. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. The Journal of clinical investigation. 2008;118(4):1244-1254.
6. Piot P, Kazatchkine M, Dybul M, Lob-Levyt J. AIDS: lessons learnt and myths dispelled. The Lancet. 2009 ;374(9685):260-263.
7. Obeagu EI. Comparative Study of Serum Iron and Hemoglobin Levels of Cord Blood of Normal Neonates and that of Maternal Blood in Federal Medical Centre Owerri. Journal of Clinical and Laboratory Research. 2021;4(1):2768-0487.
8. Obeagu EI, Aneke J, Okafor CN, Essein UC, Ochei KC, Obeagu GU. Assessment of Serum Iron Status of Malnourished Infants in Umuahia, Abia State, Nigeria. Sch J App Med Sci. 2016; 4:4384-7.
9. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471.
10. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
11. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.

12. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
13. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
14. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
15. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
16. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
17. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
18. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU. Iron and blood donation: A Review. Int. J. Curr. Res. Med. Sci. 2016;2(10):16-48.
21. Obeagu EI, Obeagu GU, Emeonye OP, Jakheng SP. An Upadte on Interleukin 6 And Iron Status of Volleyball Players. Madonna University journal of Medicine and Health Sciences. 2022;2(2):41-74.
22. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
23. Obeagu EI, Anierobi CC, Eze GC, Chukwueze CM, Makonyonga RD, Amadi NM, Hassan R. Evaluation of Plasma Levels of Interleukin 6 and Iron Status of Volleyball Players in a Nigerian University. Journal of Advances in Medical and Pharmaceutical Sciences. 2022;24(6):18-23.
24. Obeagu EI, Obeagu GU, Guevara ME, Okafor CJ, Bot YS, Eze GC, Amadi NM, Jakheng EW, Uwakwe OS. Evaluation of Plasma Levels of Interleukin 6 and Iron of Volleyball Players Based on Heights and Weight of a Nigerian University Students. Asian Journal of Medicine and Health. 2022;20(10):147-152.

25. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
27. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
28. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
29. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
30. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
31. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
32. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
33. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
34. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.

links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf

35. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
36. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
37. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
38. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
39. Obeagu E, Felix CE, MTB O, Chikodili UM, Nchekwubedi C1S, Chinedum OK. Studies on some cytokines, CD4, iron status, hepcidin and some haematological parameters in pulmonary tuberculosis patients based on duration of treatment in Southeast, Nigeria. African Journal of Biological Sciences. 2021;3(1):146-156.
40. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
41. Assadsangabi A, Evans CA, Corfe BM, Lobo A. Application of proteomics to inflammatory bowel disease research: current status and future perspectives. Gastroenterology Research and Practice. 2019.
42. Singh S, Sarma DK, Verma V, Nagpal R, Kumar M. Unveiling the future of metabolic medicine: omics technologies driving personalized solutions for precision treatment of metabolic disorders. Biochemical and Biophysical Research Communications. 2023.
43. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
44. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-18.
45. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138.
46. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
47. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT:

assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.

48. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
49. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
50. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
51. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
52. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
53. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
54. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
55. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal

of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
56. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
57. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
58. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
59. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
60. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
61. Obeagu EI, Nwazu ME, Obeagu GU. Evaluation of plasma levels of interleukin 6 and iron status based on sleeping patterns of students in a Nigerian University. Int. J. Curr. Res. Med. Sci. 2022;8(9):1-6.
62. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences. 2022;2(1):218-234.
63. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
64. Obeagu EI, Babar Q. Recent advances in understanding of Haemochromatosis: A burning issue of life. Int. J. Curr. Res. Med. Sci. 2021;7(7):23-28.
65. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-48.
66. Edward Henry SI, Obeagu EI. Assessment of the Serum Iron Status of Preeclampsia Subjects in Aba, Abia State. Elite Journal of Haematology. 2024;2(1):10-18.
67. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
68. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI:

10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.

69. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
70. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
71. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
72. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
73. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
74. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
75. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
76. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
77. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
78. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
79. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.

80. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
81. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
82. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
83. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
84. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
85. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
86. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
87. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
88. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
89. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
90. Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. Elite Journal of Health Science, 2023; 1(1):1-11
91. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. Elite Journal of Health Science, 2023; 1(1):12-22
92. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. Elite Journal of Public Health, 2023; 1 (1): 1-11
93. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 12-22
94. Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33

95. Obeagu EI, Obeagu GU. From Classroom to Home: Strengthening the Continuum of Sickle Cell Disease Knowledge. Elite Journal of Health Science, 2023; 1(1):23-29
96. Obeagu EI, Obeagu GU. Incorporating Sickle Cell Disease Curriculum in Schools: An Effective Approach. Elite Journal of Health Science, 2023; 1(1):30-36
97. Obeagu EI, Obeagu GU. Community Leaders as Educators: Mobilizing for Sickle Cell Disease Reduction. Elite Journal of Health Science, 2023; 1(1):37-43
98. Obeagu EI, Obeagu GU. Peer-to-Peer Learning Networks: Sickle Cell Disease Education Among Adolescents. Elite Journal of Public Health, 2023; 1 (1): 34-41
99. Obeagu EI, Obeagu GU. From Awareness to Action: Encouraging Adolescent Engagement in Sickle Cell Disease Prevention. Elite Journal of Public Health, 2023; 1 (1): 42-50
100. Obeagu EI, Obeagu GU. The Vital Role of Antioxidants in Enhancing Fertility and Pregnancy Success: A Review. Elite Journal of Nursing and Health Science, 2023; 1(1):1-12
101. Obeagu EI, Obeagu GU. Harnessing the Power of Antioxidant-Rich Diet for Preconception Health: A Review. Elite Journal of Health Science, 2023; 1(1):1-13
102. Obeagu EI. Unraveling Diagnostic Challenges of Aplastic Anemia in the Context of HIV: A Review. Elite Journal of Nursing and Health Science, 2023; 1(1):13-23
103. Obeagu EI. **I**mmunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. Elite Journal of Health Science, 2023; 1(1):14-24
104. Obeagu EI. Treatment Strategies for Aplastic Anemia in HIV: Current Approaches and Future Directions. Elite Journal of Laboratory Medicine, 2023; 1(1): 1-12
105. Hackl L, Itzkowitz L, Koso-Thomas M, Moorthy D, Owino V, Pachón H, Stoffel N, Zimmerman M, Raiten D, Loechl C, Datta-Mitra A. Approaches to Address the Anemia Challenge. The Journal of Nutrition. 2023;153(Suppl 1).
106. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV, 2023; 1(1): 15-28
107. Obeagu EI. Hemochromatosis and HIV: Two Conditions, One Challenge. Elite Journal of Laboratory Medicine, 2023; 1(1): 13-27
108. Obeagu EI. Iron Overload in HIV: Implications for Antiretroviral Therapy. Elite Journal of Health Science, 2023; 1(1):25-37
109. Obeagu EI. Hemochromatosis and HIV: Implications for Immune Reconstitution. Elite Journal of Health Science, 2023; 1(1):17-30
110. Obeagu EI. Ceruloplasmin and Oxidative Stress in HIV: A Review. Elite Journal of HIV, 2023; 1(1): 29-42
111. Obeagu EI. Ceruloplasmin and HIV-Associated Coagulopathies: A Review. Elite Journal of Laboratory Medicine, 2023; 1(1): 28-41
112. Obeagu EI. Ceruloplasmin and HIV-Associated Malignancies: A Review. Elite Journal of Health Science, 2023; 1(1):38-50